• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Fig Flow cytometry profiles of A cell line after


    Fig. 11. Flow cytometry profiles of A549 cell line after 3 h of incubation with biotin-C6-NLCs and C6-NLCs. 
    Fig. 12. Fluorescence microscopic images of A549 cells after 3 h incubation with biotin-C6-NLCs and C6-NLCs.
    confirmed efficient cellular uptake of biotin-NLCs. As it can be seen in Fig. 12, the fluorescent intensity of biotin-NLCs related to the C6 that entered into cells is more than that of the non-targeted NLCs.
    4. Conclusions
    In present study, we developed biotin functionalized NLCs for the SUN delivery. B-SA conjugate was synthesized and confirmed by FTIR and H NMR. The formulation variables were optimized using Design Expert Software. 516-85-8 The optimized biotin-SUN-NLCs showed acceptable particle sizes with narrow size distributions. Besides, biotin-SUN-NLCs
    S. Taymouri et al.
    showed significantly higher cytotoxic effect in lung cancer A549 cells overexpressing biotin receptor compared to that of non-targeted NLCs and free SUN. The improvement of cellular uptake of biotin-SUN-NLCs into A549 cells was also demonstrated. Taken together, biotin-SUN-NLCs can be used as an efficient targeted chemotherapy to cure a number of cancers overexpressing biotin receptors, including lung cancer. However, further study is required to confirm the therapeutic potential of biotin-SUN-NLCs in cancer therapy in vivo.
    Declaration of conflicting interests
    The authors report no conflicts of interest.
    The authors wish to thank the Research Vice Chancellery of Isfahan University of Medical Sciences for supporting this work.
    A biodegradable perivascular wrap for controlled, local and directed drug delivery,
    R. Govindan, J.N. Atkins, H.H. Gillenwater, C. Pallares, L. Tye, Multicenter, phase II trial of sunitinib in previously treated, advanced non–small-cell lung cancer, J. Clin. Oncol. 26 (2008) 650. [8] J.J. Joseph, D. Sangeetha, T. Gomathi, Sunitinib loaded chitosan nanoparticles formulation and its evaluation, Int. J. Biol. Macromol. 82 (2016) 952–958. [9] J. Varshosaz, S. Eskandari, M. Tabakhian, Production and optimization of valproic 516-85-8 nanostructured lipid carriers by the Taguchi design, Pharmaceut. Dev. Technol.  Journal of Drug Delivery Science and Technology 50 (2019) 237–247
    [10] J. Varshosaz, S. Taymouri, F. Hassanzadeh, S. Haghjooy Javanmard, M. Rostami, Folated synperonic-cholesteryl hemisuccinate polymeric micelles for the targeted delivery of docetaxel in melanoma, BioMed Res. Int. 2015 (2015). [11] T. Ramasamy, U.S. Khandasami, H. Ruttala, S. Shanmugam, Development of solid lipid nanoparticles enriched hydrogels for topical delivery of anti-fungal agent, Macromol. Res. 20 (2012) 682–692. [12] J. Emami, M. Rezazadeh, H. Sadeghi, K. Khadivar, Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of pacli-taxel using Box–Behnken design, Pharmaceut. Dev. Technol. 22 (2017) 370–382.
    [13] M. Fathi, J. Varshosaz, M. Mohebbi, F. Shahidi, Hesperetin-loaded solid lipid na-noparticles and nanostructure lipid carriers for food fortification: preparation, characterization, and modeling, Food Bioprocess Technol. 6 (2013) 1464–1475. [14] S. Das, W.K. Ng, R.B. Tan, Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative eva-luations of clotrimazole-loaded SLNs and NLCs? Eur. J. Pharm. Sci. 47 (2012) 139–151.
    [15] M. Danaei, M. Dehghankhold, S. Ataei, F. Hasanzadeh Davarani, R. Javanmard, A. Dokhani, S. Khorasani, M.R. Mozafari, Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems, Pharmaceutics 10 (2018) 57. [16] G. Abdelbary, R.H. Fahmy, Diazepam-loaded solid lipid nanoparticles: design and characterization, AAPS PharmSciTech 10 (2009) 211–219. [17] N. Sharma, P. Madan, S. Lin, Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: a co-surfactant study, Asian J. Pharm. Sci. 11 (2016) 404–416. [18] J. Varshosaz, S. Eskandari, R. Kennedy, M. Tabbakhian, M. Minaiyan, Factors af-fecting the production of nanostructure lipid carriers of valproic acid, J. Biomed. Nanotechnol. 9 (2013) 202–212. [19] V. Teeranachaideekul, E.B. Souto, V.B. Junyaprasert, R.H. Müller, Cetyl palmitate-based NLC for topical delivery of Coenzyme Q 10–Development, physicochemical characterization and in vitro release studies, Eur. J. Pharm. Biopharm. 67 (2007) 141–148. [20] S. Taymouri, J. Varshosaz, F. Hassanzadeh, S.H. Javanmard, N. Dana, Optimisation of processing variables effective on self-assembly of folate targeted Synpronic-based micelles for docetaxel delivery in melanoma cells, IET Nanobiotechnol. 9 (2015) 306–313.
    [21] M. Üner, Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems, Pharmazie 61 (2006) 375–386.